This bill amends New Jersey's medical cannabis laws to include sickle cell anemia as a qualifying medical condition for the medical use of cannabis. The addition of sickle cell anemia recognizes the chronic pain and other symptoms associated with this inherited blood disorder, allowing patients suffering from it to access medical cannabis as a treatment option.

The bill specifically inserts the phrase "sickle cell anemia" into the definition of "qualifying medical condition," thereby expanding the scope of conditions eligible for medical cannabis treatment. This change aims to provide relief to patients experiencing the debilitating effects of sickle cell anemia, aligning with the state's ongoing efforts to enhance patient care through the use of medical cannabis. The act is set to take effect immediately upon passage.

Statutes affected:
Introduced: 24:6I-3